Aether Industries Q1 FY27 Earnings Call: Partners With Dow for Silicone Import Substitution, Oil & Gas Crosses Rs. 100 Cr

Aether Industries Ltd held its Q1 FY27 earnings call on July 31, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Revenue up 27%, margin expansion across all lines

• Revenue of Rs.3,266 million in Q1 FY2026-2027 grew 27% YoY from Rs.2,566 million in Q1 FY2025-2026, driven by CEM/CRAMS scale-up and oil & gas ramp.
• EBITDA of Rs.1,028 million expanded 31% YoY; margin improved to 31.0% from 30.0% in the prior-year quarter, aided by mix shift toward higher-margin CEM.
• PAT of Rs.627 million rose 33% YoY, with net margin at 19.2% versus 18.4% in Q1 FY2025-2026, reflecting operating leverage and a fully received final insurance claim for the November 2023 fire accident.
• CAPEX of Rs.943 million in Q1 FY2026-2027; management guided full-year FY2026-2027 CAPEX at Rs.3,000–Rs.3,500 million, primarily allocated to Site 5 (Magnum, Panoli) and the new R&D facility.
• Capacity utilisation as of Q1 FY2026-2027 stood at Site 2 (74%), Site 3 (69%), and Site 4 (59%); inventory elevated for strategic raw material and semi-finished positioning ahead of Site 3++ and Site 5 ramp-up.

Ten new marquee clients; oil & gas surges past Rs.100 Cr

• 10 new marquee clients onboarded in Q1 FY2026-2027, and the company cleared 9+ customer and certification audits; management described demand signals in FY2026-2027 as the "strongest ever seen" from order visibility and rising urgency from Western customers.
• Oil & gas revenue reached ~Rs.100 crores (~Rs.1,000 million) in Q1 FY2026-2027, largely driven by Baker Hughes, scaling from Rs.45 crores in Q1 FY2025-2026; management sees clear line of sight for further demand.
• LSM volume declined 22.5% YoY in Q1 FY2026-2027 due to production-line reallocation to CEM, but management confirmed no decline in demand; LSM pricing improved 22.5% YoY, partially offsetting the volume impact.
• Multi-year supply agreement with Milliken spans 9–10 years for a single strategic molecule; new products for Baker Hughes were added between Q4 FY2025-2026 and Q1 FY2026-2027. Management declined to quantify expected revenue over 2–3 years.
• Management targets 70%+ revenue contribution from CRAMS and CEM models in the coming years (period unspecified), up from the current level of above 50%; LSM is expected to contribute only 30–35% of total revenue in the future (period unspecified).

Exclusive multi-year research program targets India's $1 Bn silicone import market

• Exclusive research partnership with Dow announced on 30 July 2026 (Q1 FY2026-2027) for developing novel manufacturing technologies for foundational silicones; each party is limited to work only with the other in this program.
• Program targets India's ~$1 billion silicones market, which is entirely import-dependent (China, Germany, US) with a projected 7–10% CAGR (period unspecified); management stated the partnership aims to address the "billion-dollar Indian import substitution market for silicones."
• Aether conducts the bulk of R&D and pilot-plant scale-up at Surat, Gujarat; Dow funds the program and contributes deep process know-how. Senior leadership from both Dow India and Dow US provided quotes for the announcement.
• Path to commercialization spans four stages: R&D and process development → pilot-scale validation → definitive commercial framework with Dow → potential CAPEX commitment for a dedicated site. No revenue timeline or commercialization horizon was provided.
• Platform technology for silicones opens future applications across semiconductors, electronics, coatings, formulations, and encapsulants; management described the relationship as becoming "hardcore inseparable" upon successful scale-up expected within a few months to a few years (period unspecified).
• Silicone R&D program is in early stage; application testing expected to begin in "a few years" (multi-year timeline, no specific FY). No specific FY or quarter was attached to this timeline.

Specialty monomers for 5G/AI; 400-ton capacity set to triple by 2030

• Entry into specialty monomers for 5G/AI high-speed circuit boards at Site 5 (Magnum, Panoli); products include sealing coupling agents and low-dielectric resins, positioned upstream of semiconductor supply chains with average product value of ~$50/kg and no domestic manufacturer currently.
• Initial capacity of 400 tons for semiconductor materials, expected to triple "by 2030"; management noted the India semiconductor and electronics market is on a path from ~$50 billion today to $110 billion in 2030, creating an import-substitution and export opportunity.
• Commercial supply of semiconductor chemicals commenced on Site 3 in small quantities; the large-scale 45 tons/month capacity (three streams of 15 tons each) at Site 5 is targeted to go online by end of September 2026 (Q2 FY2026-2027).
• Commercialisation of one production block for semiconductor materials is expected by Q3 FY27. No semiconductor orders were disclosed for competitive reasons; management will announce contracts once signed with multinational customers.
• Applying for benefits under ISM 2.0 (government semiconductor scheme), but management stated the structure of the scheme is still unclear; the company differentiates via a capital-light R&D and pilot-plant model rather than heavy-capex purification scale-up pursued by competitors.

CEM margin band held at 28–30%; Site 5 ramp begins

• CEM business EBITDA margin guidance reiterated at 28–30% (ongoing); management declined to provide product- or segment-specific margin guidance beyond this consolidated band for the CEM portfolio.
• Magnum (Site 5, Panoli) comprises 16 production blocks with a total investment of Rs.2,200–Rs.2,300 crores; Phase 1 is online and several customers have completed pre-audits. Management expects an asset turn of 1.5–1.75 once fully operational.
• New LSM product revenue contribution from Site 5 is expected from Q2 FY2026-2027; the first set of three new LSM products (pharma, agrochemicals, material science) are priced at ~$30–$40/kg and are import substitutes made in India for the first time.
• Site 3++ commissioned in February 2026 (FY2025-2026) is ramping faster than planned, with meaningful commercial contribution materialising ahead of schedule.
• New R&D facility with ~15 new labs and approximately 160 cumulative fume hoods is on track for commissioning in FY 2027-2028 (FY28).
• Oil & gas segment has grown from 0% to ~20% of revenue over the past two years and is expected to increase further, though no firm timelines were given pending contract signings; Baker Hughes remains the largest customer in this vertical.

25–30% compounding growth target; execution risks acknowledged

• Core specialty + CRAMS/CEM business expected to deliver 25–30% compounding growth (period unspecified); management attributed the outlook to strong order visibility, rising Western customer urgency, and 4–5 undisclosed partnerships beyond Dow across pharma, agrochemicals, materials science, and oil & gas.
• Management acknowledged execution bandwidth as a key risk, prioritising safety and operational execution; expansion is being approached pragmatically with concurrent R&D, pilot-plant, and manufacturing investments at the promoter-family-led company.
• Backward integration is pursued wherever required, especially to reduce China dependency; over the five fiscal years through FY2025-2026, management did not disclose specific spending on backward integration.
• Working capital discipline remains a priority; inventory is elevated due to strategic raw material and semi-finished positioning for Site 3++ and Site 5, with a progressive decline expected as revenues from these sites materialise.
• No product/segment-specific margin guidance beyond the CEM 28–30% band; management declined to quantify expected revenue from key customers (Baker Hughes, Milliken) over the next 2–3 years. LSM faces 30–35% price declines from Chinese competitors post-COVID, but management reported no market share loss.